Korean J Med.  2017 Oct;92(5):443-449. 10.3904/kjm.2017.92.5.443.

SGLT2 Inhibitors and Ketoacidosis: Pathophysiology and Management

Affiliations
  • 1Division of Endocrinology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea. kyh@kirams.re.kr

Abstract

Sodium-glucose cotransporter 2 inhibitors are antidiabetic drugs that increase urinary glucose excretion by inhibiting proximal tubular reabsorption of glucose in the kidney. Some sodium-glucose cotransporter 2 inhibitors have been shown to afford effective glycemic control and to decrease the risks of major adverse cardiovascular events. However, these drugs may increase the risk of diabetic ketoacidosis. This is a rare complication that occurs in less than 0.1% of treated patients with type 2 diabetes. The condition may be euglycemic, and is triggered by controllable precipitating factors such as surgery, infection, and insulin reduction or omission. It is important to understand individual patient profiles and to prevent diabetic ketoacidosis by appropriate prescribing, by withholding sodium-glucose cotransporter 2 inhibitors when indicated, and by counseling patients on sick day management.

Keyword

Sodium-glucose transporter 2; Diabetic ketoacidosis; Ketone bodies

MeSH Terms

Counseling
Diabetic Ketoacidosis
Glucose
Humans
Hypoglycemic Agents
Insulin
Ketone Bodies
Ketosis*
Kidney
Precipitating Factors
Sick Leave
Sodium-Glucose Transporter 2
Glucose
Hypoglycemic Agents
Insulin
Ketone Bodies
Sodium-Glucose Transporter 2
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr